Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)

R. Gervais, A Ducoloné, Jean-Luc Breton et al. · Annals of Oncology · 2004

Cited by 116 works. doi:10.1093/annonc/mdi018

Authors

References